KATHERINE
2019
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
In 1,486 patients with HER2+ early breast cancer and residual invasive disease after neoadjuvant taxane + trastuzumab, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease-free survival events compared with trastuzumab.
Result
Efficacy: Invasive disease-free survivalHR 0.5
Below 1 favours trastuzumab emtansine (T-DM1), above 1 favours trastuzumab.
- Absolute difference
- 11.3 points
The absolute difference is derived from the event rates.
Also reported: 8.4-yr OS HR 0.66.
- Subtopic
- HER2+ residual disease
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- von Minckwitz G, et al. N Engl J Med. 2019;380(7):617-628; Geyer CE, et al. N Engl J Med. 2025;392(3):249-257.doi 10.1056/NEJMoa1814017
Discussion & critique
Defined post-neoadjuvant escalation in HER2+ early breast cancer with residual disease as standard of care.